Exploring the Potential Synergistic Action of Spironolactone on Nitric Oxide-Enhancing Therapy: Insights From the African-American Heart Failure Trial

Journal of Cardiac Failure

Volumn 14, Issue 9, 2008, Pages 718-723

  Ghali, Jalal K ^a   Tam, S William ^b   Sabolinski, Michael L ^b   Taylor, Anne L ^c   Lindenfeld, Joann ^d   Cohn, Jay N ^e   Worcel, Manuel ^b  

^a WAYNE STATE UNIVERSITY   (United States)

^b NitroMed Inc   (United States)

^c NewYork Presbyterian Hospital   (United States)

^d UNIVERSITY OF COLORADO   (United States)

^e UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

Heart failure; race

Indexed keywords

HYDRALAZINE PLUS ISOSORBIDE DINITRATE; PLACEBO; SPIRONOLACTONE;

ADULT; AFRICAN AMERICAN; AGED; ARTICLE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG POTENTIATION; FEMALE; HEART FAILURE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADULT; AFRICAN AMERICANS; AGED; CLINICAL TRIALS, PHASE III AS TOPIC; DRUG COMBINATIONS; DRUG SYNERGISM; FEMALE; HEART FAILURE; HUMANS; HYDRALAZINE; ISOSORBIDE DINITRATE; MALE; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; NITRIC OXIDE DONORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETROSPECTIVE STUDIES; SPIRONOLACTONE;

EID: 55149111172     PISSN: 10719164     EISSN: 15328414     Source Type: Journal    
DOI: 10.1016/j.cardfail.2008.07.189     Document Type: Article

References (36)

1. Weber K.T. Aldosterone in congestive heart failure. N Engl J Med 345 (2001) 1689-1697
2. Struthers A.D. Aldosterone: cardiovascular assault. Am Heart J 144 (2002) S2-S7
3. Stier Jr. C.T., Chander P.N., and Rocha R. Aldosterone as a mediator in cardiovascular injury. Cardiol Rev 10 (2002) 97-107
4. Pitt B., Zannad F., Remme W.J., et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341 (1999) 709-717
5. Pitt B., Remme W., Zannad F., et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348 (2003) 1309-1321
6. Ikeda U., Kanbe T., Nakayama I., et al. Aldosterone inhibits nitric oxide synthesis in rat vascular smooth muscle cells induced by interleukin-1β. Eur J Pharmacol Mol Pharmacol Sect 290 (1995) 69-73
7. Farquharson C.A., and Struthers A.D. Aldosterone induces acute endothelial dysfunction in vivo in humans: evidence for an aldosterone-induced vasculopathy. Clin Sci 103 (2002) 425-431
8. Nagata D., Takahashi M., Sawai K., et al. Molecular mechanism of the inhibitory effect of aldosterone on endothelial NO synthase activity. Hypertension 48 (2006) 165-171
9. Bauersachs J., and Fraccarollo D. Endothelial NO synthase target of aldosterone. Hypertension 48 (2006) 27-28
10. Kotlyar E., Vita J.A., Winter M.R., et al. The relationship between aldosterone, oxidative stress, and inflammation in chronic, stable human heart failure. J Card Fail 12 (2006) 122-127
11. Farquharson C.A., and Struthers A.D. Spironolactone increases nitric oxide in bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure. Circulation 101 (2000) 594-597
12. Bauersachs J., Heck M., Fraccarollo D., et al. Addition of spironolactone to angiotensin-converting enzyme inhibition in heart failure improves endothelial vasomotor dysfunction. J Am Coll Cardiol 39 (2002) 351-358
13. Schafer A., Fraccarollo D., Hildemann S.K., et al. Addition of the selective aldosterone receptor antagonist eplerenone to ACE inhibition in heart failure: effect on endothelial dysfunction. Cardiovasc Res 58 (2003) 655-662
14. Macdonald J.E., Kennedy N., and Struthers A.D. Effects of spironolactone on endothelial function, vascular angiotensin converting enzyme activity, and other prognostic markers in patients with mild heart failure already taking optimal treatment. Heart 90 (2004) 765-770
15. Thai H.M., Do B.Q., Tran T.D., et al. Aldosterone antagonism improves endothelial-dependent vasorelaxation in heart failure via upregulation of endothelial nitric oxide synthase production. J Card Fail 12 (2006) 240-245
16. Sartorio C.L., Fraccarollo D., Galuppo P., et al. Mineralocorticoid receptor blockade improves vasomotor dysfunction and vascular oxidative stress early after myocardial infarction. Hypertension 50 (2007) 919-925
17. Taylor A.L., Ziesche S., Yancy C., et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med 351 (2004) 2049-2057
18. McNamara D.M., Tam S.W., Sabolinski M.L., et al. Aldosterone synthase promoter polymorphism predicts outcome in African-Americans with heart failure: results from the A-HeFT Trial. J Am Coll Cardiol 48 (2006) 1277-1282
19. Fraccarollo D., Galuppo P., Heldemann S., et al. Additive improvement of left ventricular remodeling and neurohormonal activation by aldosterone receptor blockade with eplerenone and ACE inhibition in rats with myocardial infarction. J Am Coll Cardiol 42 (2003) 1666-1673
20. Berry C., Murphy N., De Vito G., et al. Effects of aldosterone receptor blockade in patients with mild-moderate heart failure taking a beta-blocker. Eur J Heart Fail 9 (2007) 429-434
21. MacFayden R.J., Carr C.S., and Stuthers A.D. Aldosterone blockade reduces vascular collagen turnover, improves heart rate variability and reduces early morning rise in heart rate in heart failure patients. Cardiovasc Res 35 (1997) 30-34
22. Cittadini A., Monti M.G., Isgaard J., et al. Aldosterone receptor blockade improves left ventricular remodeling and increases ventricular fibrillation threshold in experimental heart failure. Cardiovasc Res 58 (2003) 555-564
23. Macdonald J.E., and Struthers A.D. What is the optimal serum potassium level in cardiovascular patients?. J Am Coll Cardiol 43 (2004) 155-161
24. Chan A.K., Sanderson J.E., Wang T., et al. Aldosterone receptor antagonism induces reverse remodeling when added to angiotensin receptor blockade in chronic heart failure. J Am Coll Cardiol 50 (2007) 591-596
25. Tsutamoto T., Wada A., Maeda K., Mabbbbuchi N., Hayaashi M., Tsutsui T., et al. Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure. J Am Coll Cardiol 37 (2001) 1228-1233
26. Malinski T. Understanding nitric oxide physiology in the heart: a nanomedical approach. Am J Cardiol 96 Suppl (2005) 13i-24i
27. Androne A.S., Hryniewicz K., Hudaihed A., Dimayuga C., Yasskiy A., Qureshi G., et al. Comparison of metabolic vasodilation in response to exercise and ischemia and endothelium-dependent flow-mediated dilation in African-American versus non-African-American patients with chronic heart failure. Am J Cardiol 97 (2006) 685-689
28. Macdonald J.E., and Struthers A.D. What is the optimal serum potassium level in cardiovascular patients?. J Am Coll Cardiol 43 (2004) 155-161
29. Tadder S., Mattei P., Virdis A., Sudano I., Ghiadoni L., and Salvetti A. Effect of potassium on vasodilation to acetylcholine in essential hypertension. Hypertension 23 (1994) 485-490
30. Cohn J.N., Tam S.W., Anand I.S., et al. Isosorbide dinitrate and hydralazine in a fixed-dose combination produces regression of left ventricular remodeling in a black population with heart failure: results from A-HeFT. J Card Fail 13 (2007) 331-339
31. Berry C., and McMurray J. Serious adverse events experienced by patients with chronic heart failure taking spironolactone. Heart 85 (2001) e8-e9
32. Bozkurt B., Agoston I., and Knowlton A.A. Complications of inappropriate use of spironolactone in heart failure: when an old medicine spirals out of new guidelines. J Am Coll Cardiol 41 (2003) 211-214
33. Svensson M., Gustafsson F., Galatius S., Hildebrandt P.R., and Atar D. Hyperkalaemia and impaired renal function in patients taking spironolactone for congestive heart failure: retrospective study. BMJ 327 (2003) 1141-1142
34. Wrenger E., Muller R., Moesenthin M., Welte T., Frolich J.C., and Neumann K.H. Interaction of spironolactone with ACE inhibitors or angiotensin receptor blockers: analysis of 44 cases. BMJ 327 (2003) 147-149
35. Juurlink D.N., Mamdani M.M., Lee D.S., Kopp A., Austin P.C., Laupacis A., et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 351 (2004) 543-551
36. Tam S.W., Worcel M., Sabolinski M.L., Packer M., and Cohn J.N. Lack of bioequivalence between different formulations of isosorbide dinitrate and hydralazine and the fixed-dose combination of isosorbide dinitrate/hydralazine. The V-HeFT Paradox. Clin Pharmacokinet 46 (2007) 885-895